ArticleChronic respiratory disease
Trends in chronic ischemic heart disease mortality in patients with interstitial lung disease in the United States from 1999 to 2023.
Article in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BackgroundInterstitial lung disease (ILD) patients often have comorbid chronic ischemic heart disease (CIHD), which may worsen prognosis. Large-scale studies on long-term CIHD mortality trends in ILD patients are lacking. This study analyzes CIHD-related mortality trends in US adults with ILD from 1999 to 2023.MethodsCIHD-related mortality data were extracted from the CDC WONDER database for ILD patients aged ≥25 years. International Classification of Diseases, 10th Revision (ICD-10) codes J84.1, J84.8, J84.9 identified ILD, and code I25 identified CIHD. Age-adjusted mortality rates (AAMR), annual percentage change (APC), and average annual percentage change (AAPC) per 100,000 were calculated using Joinpoint regression.ResultsBetween 1999 and 2023, there were 92,779 CIHD-related deaths among U.S. decedents with interstitial lung disease (ILD, listed as an underlying or contributing cause of death in death certificates); this accounted for a substantial proportion of cardiovascular-related deaths in this decedent population. The overall AAMR showed a slight upward trend (AAPC=0.51%), but with significant nonlinearity: a decrease from 2003-2018 (APC=-1.29%), increased sharply from 2018 to 2021 (APC = 9.75%), with the increase concentrated during the COVID-19 pandemic years. The age-adjusted mortality rate rose modestly from 1.54 per 100,000 in 2018 to 1.60 in 2019 (+3.9%), then surged to 1.73 in 2020 (+8.1%) and peaked at 1.98 in 2021 (+14.5% from 2020). After 2021, mortality declined to 1.88 in 2023. Mortality was higher in men, non-Hispanic Whites, adults >85 years, and in southern and nonmetropolitan areas. Each subgroup showed a significant increase in mortality during 2020-2021, coinciding with the pandemic, while pre-pandemic trends were more gradual.ConclusionsCIHD-related mortality in ILD patients showed a fluctuating upward trend over 25 years, with a significant jump during the COVID-19 pandemic. This underscores the systemic impact of public health emergencies on cardiovascular health in vulnerable populations. Cardiovascular risk assessment and management should be integrated into routine ILD care, with tailored strategies for high-risk groups and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.